SCHEMBL8043513

SCHEMBL8043513

Cc1ccc(Cl)cc1-n1ncc(C#N)c1N

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
ALDH1A1 P00352 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
KDM4E B2RXH2 3/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
RXRG P48443 1/20 0.45
XDH P47989 2/20 0.43
HPGD P15428 1/20 0.41
TP53 P04637 3/20 0.41
LMNA P02545 2/20 0.40
JAK2 O60674 2/20 0.40
POLB P06746 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
SCN9A Q15858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10967579 0.89 KMT2A (0.52) KMT2AALDH1A1NPSR1KDM4EMEN1
SCHEMBL1457404 0.86 KMT2A (0.49) KMT2AALDH1A1NPSR1KDM4EMEN1
SCHEMBL838991 0.86 KMT2A (0.62) KMT2AALDH1A1NPSR1KDM4EMEN1
SCHEMBL838963 0.83 KMT2A (0.61) KMT2AALDH1A1NPSR1KDM4EMEN1
SCHEMBL838866 0.83 KMT2A (0.52) KMT2AALDH1A1NPSR1KDM4EMEN1
SCHEMBL8052663 0.83 KMT2A (0.47) KMT2AALDH1A1NPSR1KDM4EMEN1
SCHEMBL10608500 0.83 KMT2A (0.49) KMT2AALDH1A1NPSR1KDM4EMEN1
SCHEMBL8040568 0.83 KMT2A (0.47) KMT2AALDH1A1KDM4EMEN1MAPT
SCHEMBL10619481 0.82 KMT2A (0.50) KMT2AALDH1A1NPSR1KDM4EMEN1
SCHEMBL10987859 0.81 KMT2A (0.49) KMT2AALDH1A1NPSR1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648085-B2 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-11 US disclosed
US-8648085-B2 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-11 US disclosed
US-20110015193-A1 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-20 US disclosed
US-20110015193-A1 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-20 US disclosed
WO-2009068617-A1 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TEATMENT OF CNS DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015193-A1 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS PDE9A, PDE7A, PDE1C KMT2A 1720/4885ALDH1A1 127/4885NPSR1 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.